Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapies for musculoskeletal and rare neuromuscular diseases. Its lead candidate, EDG-5506, is an orally administered small molecule designed to selectively limit injurious hypercontraction stress in dystrophinopathies including Duchenne and Becker muscular dystrophy. EDG-5506 is currently advancing in a Phase 1 randomized, placebo-controlled Single and Multiple Ascending Dose trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and adults with BMD. The company completed a $95 million Series C financing to advance clinical development of EDG-5506 and its other rare disease programs. Proceeds are also intended to support potential future in-licensing opportunities and clinical collaborations in rare diseases. Edgewise was founded in 2017. Edgewise Therapeutics is a preclinical company developing first-in-class small-molecule therapies for high-morbidity musculoskeletal diseases. The company uses a muscle physiology platform to identify novel targets intended to arrest muscle damage, limit inflammatory and fibrotic responses, and preserve muscle integrity and function. Its lead product candidate is being advanced toward clinical development for Duchenne and Becker muscular dystrophies. Edgewise says its approach aims to reduce muscle breakdown and normalize muscle function to decrease mortality and improve quality of life. The company was founded in 2017 and is based in Boulder, Colorado. It closed a $50 million Series B to fund clinical advancement of the lead candidate and expansion of its pipeline.

Total raised

$145M

Funding rounds

2

Latest round

Series C

Latest activity

Dec 2020